登录 | 注册    关注公众号  
微信公众号
搜索

GP120 (HIV)信息

英文名称:HIV envelope protein gp120
中文名称:HIV包膜蛋白gp120
靶点别称:HIV Envelope Protein gp120
上市药物数量:2
临床药物数量:6
最高研发阶段:批准上市

GP120 (HIV)产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
 
评论(0)
 

GP120 (HIV) 分子别名

GP120 (HIV) 分子背景

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses. Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

GP120 (HIV) 前沿进展

GP120 (HIV)上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Radha-108 批准上市 Biomix Network Receptol HIV感染 详情
Fostemsavir Tromethamine BMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrug 批准上市 百时美施贵宝 Rukobia EU HIV感染 Viiv Healthcare Bv 2020-07-02 HIV感染 详情

GP120 (HIV)临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung) 临床一期 Polymun Scientific HIV感染 详情
A-1801 A-1801 临床阶段不明 武汉波睿达生物科技有限公司 HIV感染 详情
Elipovimab GS-9722 临床一期 吉利德 HIV感染 详情
FB-1002(Frontier Biotechnologies) FB-1002(前沿生物) 临床一期 前沿生物药业(南京)股份有限公司, 中国科学院上海药物研究所 新型冠状病毒肺炎 详情
Suvizumab KD-247 Kaketsuken 详情
SAR-441236 (National Institute of Allergy and Infectious Diseases) SAR-441236 National Institute Of Allergy And Infectious Diseases (Niaid), 赛诺菲, The Scripps Research Institute Inc, 美国国立卫生研究院 详情
Env-2-3 Env-2-3 诺华制药 详情
PDPHV-201401 PDPHV-201401 National Institute Of Allergy And Infectious Diseases (Niaid) 详情
Teropavimab 3BNC117-LS; 3BNC117; GS-5423 临床二期 The Rockefeller University HIV感染, 获得性免疫缺损综合征 详情
Zinlirvimab 10-1074; 10-1074-LS; GS-2872 临床二期 The Rockefeller University HIV感染 详情

消息提示

请输入您的联系方式,再点击提交!

确定